Rapidscan Pharma Solutions

Rapidscan Pharma Solutions, Inc. is a company founded in 2010 that specializes in the development, manufacturing, and marketing of Regadenoson, a pharmacological stress agent utilized in the diagnosis and risk assessment of cardiovascular disease. The company holds licenses to sell Regadenoson in various regions, including Europe, Latin America, Japan, Australia, New Zealand, and Israel. This product plays a critical role in the diagnosis of coronary artery disease, a condition affecting over 15 million individuals in Europe, with approximately 1.5 million patients undergoing myocardial perfusion imaging procedures annually. As of January 2017, Rapidscan operates as a subsidiary of GE Healthcare, benefiting from its resources and expertise in the healthcare sector.